*Jupiter Biosciences CMP Rs 78 is the only company in the world to have integrated model from raw materials to finished dosage form in ‘peptides’ and has manufacturing presence for peptides in Europe and the US. It is reportedly doing placement at hefty premium to current price and also unlocking value of subsidiaries. Low market cap makes Jupiter vulnerable for a takeover bid. It may be recalled that Ranbaxy earlier had a ‘look’ at the company. Recent Biocon-Amilyn tie up and Neuland Labs foray into peptides has put this pharmaceutical segment in limelight. High B.V. of Rs 203 makes the stock good bet at current levels for target price of Rs 150.
*For the week ahead chartists predict trading range of 16,400-17,180 for the Sensex and 4,840-5,180 for the Nifty.
*Supports for the week would be at 16,560 and 15,380 and 4,920 and 4,840.
*Expect resistance to indices at 16,960 and 17,180 and 5,050 and 5,160.
*Be bearish only below 16,300 or 4,850 levels in indices on closing basis.
*Sharp selling not ruled out at psychological level of 17,000.
*Short term traders can stay on long side if Nifty trades steadily above 5,000 level.
* Shanthi Gears has cancelled entire distributors and dealers network in the name of providing better service to customers. What is the company upto?
* 3i Infotech scrip has shot up smartly on the back of a QIP placement planned by the company. Take this opportunity to book profit
* Lincoln Pharma, a dividend paying pharma company, is available at low valuation. Investors may accumulate on declines.
* Sharyans Resources a company into broking and real estate is available at low price. This stock, which had touched Rs.579 during the boom, is now available at Rs.80. A long-term stock for patient investors.
* SEL Manufacturing Company hopes to complete its 10 MW power plant by January 2010.
* Pipavav Shipyard IPO oversubscribed 8.21 times. Its grey market premium was quoting @ Rs.3-4 per share while the premium for Oil India is quoting @ Rs.34-36 per share and Jindal Cotex @ Rs.4-5.
No comments:
Post a Comment